Importantly, we found that activation of PKCδ boosts the invasiveness of GBM cells by stimulating NOTCH2 signaling, which has been considered a novel therapeutic target for GBM treatment [8, 9]. The gene discussed is NOTCH2; the disease is glioblastoma.